B A Lashner1, B D Shapiro, A Husain, J R Goldblum. 1. Department of Gastroenterology, Center for Inflammatory Bowel Disease, Cleveland Clinic Foundation, Ohio 44195, USA.
Abstract
OBJECTIVE: Immunohistochemical staining for p53 suppressor gene mutations is sensitive and, therefore, has potential for use as a complementary test for dysplasia to improve ulcerative colitis (UC) cancer surveillance program performance. METHODS: A cohort of 95 patients with long standing pan-UC enrolled in a surveillance program was studied. Archival colonic biopsy specimens were stained for p53 mutations and clinical information was obtained from medical records. RESULTS: The 37 patients who developed p53 mutations were significantly more likely to develop dysplasia or cancer (relative risk [RR] 4.53, 95% confidence interval [CI] 2.16-9.48). The p53 mutations developed approximately 8 months before low grade dysplasia, 26 months before high grade dysplasia, and 38 months before cancer. Three of seven cancer patients with p53 mutations had Dukes' stage C or D, whereas only one of five cancer patients without p53 mutations had Dukes' C or D; all three patients who died from metastatic cancer had p53 mutations (three of 37 vs 0 of 58, p < 0.03). Folic acid supplementation had a small, significant protective effect for p53 mutations (RR 0.97, CI 0.94-1.00). CONCLUSION: p53 Mutations 1) are associated with, and likely precede, dysplasia and cancer, 2) are associated with cancer-related mortality, and 3) may possibly be prevented by folic acid supplementation.
OBJECTIVE: Immunohistochemical staining for p53 suppressor gene mutations is sensitive and, therefore, has potential for use as a complementary test for dysplasia to improve ulcerative colitis (UC) cancer surveillance program performance. METHODS: A cohort of 95 patients with long standing pan-UC enrolled in a surveillance program was studied. Archival colonic biopsy specimens were stained for p53 mutations and clinical information was obtained from medical records. RESULTS: The 37 patients who developed p53 mutations were significantly more likely to develop dysplasia or cancer (relative risk [RR] 4.53, 95% confidence interval [CI] 2.16-9.48). The p53 mutations developed approximately 8 months before low grade dysplasia, 26 months before high grade dysplasia, and 38 months before cancer. Three of seven cancerpatients with p53 mutations had Dukes' stage C or D, whereas only one of five cancerpatients without p53 mutations had Dukes' C or D; all three patients who died from metastatic cancer had p53 mutations (three of 37 vs 0 of 58, p < 0.03). Folic acid supplementation had a small, significant protective effect for p53 mutations (RR 0.97, CI 0.94-1.00). CONCLUSION:p53 Mutations 1) are associated with, and likely precede, dysplasia and cancer, 2) are associated with cancer-related mortality, and 3) may possibly be prevented by folic acid supplementation.
Authors: Jeffrey W Nathanson; Nicole E Yadron; Jeanne Farnan; Sydney Kinnear; John Hart; David T Rubin Journal: Dig Dis Sci Date: 2007-08-04 Impact factor: 3.199
Authors: S Fujii; T Fujimori; H Kawamata; J Takeda; K Kitajima; F Omotehara; T Kaihara; T Kusaka; K Ichikawa; Y Ohkura; Y Ono; J Imura; S Yamaoka; C Sakamoto; Y Ueda; T Chiba Journal: Gut Date: 2004-05 Impact factor: 23.059
Authors: Pavel Wohl; Tomas Hucl; Pavel Drastich; David Kamenar; Julius Spicak; Eva Honsova; Eva Sticova; Alena Lodererova; Jan Matous; Martin Hill; Petr Wohl; Milos Kucera Journal: World J Gastroenterol Date: 2013 Impact factor: 5.742
Authors: J B Kisiel; T C Yab; F T Nazer Hussain; W R Taylor; M M Garrity-Park; W J Sandborn; E V Loftus; B G Wolff; T C Smyrk; S H Itzkowitz; D T Rubin; H Zou; D W Mahoney; D A Ahlquist Journal: Aliment Pharmacol Ther Date: 2013-01-24 Impact factor: 8.171